August 26, 2024 7:35am
Stocks are coming off of a mixed week, the rebound was enhanced by small cap Russell 2000 adding 3% following Powell’s comments. There will be volatility!
News: bluebird bio (BLUE at $0.68) received NON-COMPLIANCE notices on 8/20/24 from Nasdaq having not yet filed its 10-Q Reports, Q4/23, Q1/24 and Q2/24 Form as to 10-Q Nasdaq Listing Rule 5250(c)(1).
Pre-open Indications: 1 Sell into Strength, 1 Positive and 2 Negative Indications
There is no breadline for share pricing and fact-based intelligence! A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations.
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Monday: The pre-open Dow futures are UP +0.12% or (+49 points), the S&P futures are UP +0.13% or (+7 points) and the Nasdaq futures are UP +0.02% or (+4 points)
Stock futures are very lean Monday, 8/26/24
European stocks were trading in mixed territory,
Asia-Pacific markets were also mixed.
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Stocks are coming off of a strong week that was highlighted by comments from Fed Chair Jerome Powell that interest rates cuts are on the horizon. Wall Street has been anxiously awaiting a rate cut, especially in light of some worrying economic data that sparked a sell-off at the beginning of August and worried investors that elevated borrowing costs could damage the U.S. economy. <CNBC>
Friday: The Dow closed UP +462.30 points or +1.14%, the S&P closed UP +63.97 points or +1.15% while the Nasdaq closed UP +258.44 points or +1.47%
- Friday’s advance/decline line ended with a positive close of 28 incliner, 5 decliners and 2 flats
Economic Data Docket: initial jobless claims are due out on Thursday at 8:30 a.m., followed by the July personal consumption expenditures reading on Friday.
Friday’s RegMed Investors (RMi) Closing bell: “time has come to look forward to Labor Day and end of summer’s share pricing’s flights. 1 week or 5 sessions (for a few days off and an escape from alternating share pricing) to go until September.” … https://www.regmedinvestors.com/articles/13588
Q3/24:
- August – I neutral, 7 positive and 8 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength:
Friday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
CRISPR Therapeutics (CRSP) closed up +$1.35 after Thursday’s -$2.49, Wednesday’s +$0.92, Tuesday’s -$0.76 and Monday’s +$1.98 with a positive +$0.21 or +0.43%
Positive Indication:
Friday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Ionis Pharmaceuticals (IONS -$0.62 after Thursday’s -$0.64, Wednesday’s +$0.85, Tuesday’s -$0.31 and Monday’s +$1.18 with a positive +$0.96 or +2.05% aftermarket
Negative Indications:
Friday, Thursday and Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Intellia Therapeutics (NTLA) closed up +$0.75 after Thursday’s -$0.61 and Wednesday’s +$0.43 with a negative -$0.07 or -0.30%
Agenus (AGEN) closed up +$0.36 after Thursday’s +$0.28 with a negative -$0.04 or -0.69%
The BOTTOM LINE: The last day’s/sessions of summer are this week – intend to enjoy a few.
After Friday’s fallen, I’d buy a few of them up and I’d take some gains!
August’s 3rd full week:
- Friday ended with a positive close of 28 incliner, 5 decliners and 2 flats
- Thursday ended with a negative close of 2 incliners, 29 decliners and 4 flats
- Wednesday ended with a positive close of 29 incliner, 3 decliners and 3 flats
- Tuesday ended with a negative close of 8 incliner, 24 decliners and 3 flats
- (8/19) Monday ended with a positive close of 27 incliner, 6 decliners and 2 flats
Friday’s toll:
- 3 outperformers - Beam Therapeutics (BEAM), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
- 3 fallen - Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)
A quote to ponder, “the economy is "not out of the woods yet" regarding a recession. While the economy is slowing, the labor market is cooling, inflation is trending downward, and the Federal Reserve is expected to cut rates, the implications for individuals "depends on the phase of life you're in." < Providence Financial & Insurance Services President Anthony Saccaro>
Should investors to gradually shift their cash into core bonds …
- With a Fed rate cut on the horizon, bonds may enter a period of outperformance. He cites historical data: out of 12 Fed cutting cycles, "bonds outperformed cash by an average of 8%, so when rates come down, bonds typically do better than cash." <Sébastien Page, T. Rowe Price Global Head of Multi-Asset and Chief Investment Officer>
As interest rates begin to go down, cell and gene therapy equities could also look more attractive at these lows with the overall sector benefiting.
I advise investing in revenue driven, collaborative partnered and solid runway funded companies like
- Alnylam Pharmaceuticals (ALNY),
- CRISPR Therapeutics (CRSP),
- Lenz Therapeutics (LENZ),
- Ionis Pharmaceuticals (IONS) and
- Vericel (VCEL)
… calling out the few 2027 runways.
Think a game of monopoly and follow RMi’s interchanges to gain profit moves or recoup losses – eat the popcorn and ponder ANY moves!
- Short on words, long on being Judicious!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer, x-FBI, x-corporate manager and officer, an adjunct business school (MBA) professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and just about … everything!
- As a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.
TRUST but, VERIFY!
Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts to filter out or lessen the noise of back-and-forth share pricing from the sector rotation.
- The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
